BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

On Monday, Cardinal Health Inc (CAH) stock saw a modest uptick, ending the day at $120.03 which represents a slight increase of $1.25 or 1.05% from the prior close of $118.78. The stock opened at $118 ...

On Monday, Fulcrum Therapeutics Inc (FULC) stock saw a modest uptick, ending the day at $3.03 which represents a slight increase of $0.02 or 0.66% from the prior close of $3.01. The stock opened at $3 ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Leerink Partners, a leading investment bank specializing in healthcare, is pleased to announce the addition of Holden Hodgson as Senior Managing Director, Derivatives. Mr. Hodgson will be based in the ...

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), retaining the price target ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced ...

The good news from Monday’s results, according to Leerink Partners’ David Risinger, is that icotrokinra’s efficacy seems ...

CVS Health has added four new board members, including the CEO of a hedge fund that has been critical of the struggling ...